Brokerages Anticipate Viracta Therapeutics, Inc. (NASDAQ:VIRX) to Announce -$0.32 Earnings Per Share

Equities research analysts expect Viracta Therapeutics, Inc. (NASDAQ:VIRXGet Rating) to report earnings of ($0.32) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Viracta Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.32) and the highest estimate coming in at ($0.31). Viracta Therapeutics posted earnings per share of $0.38 during the same quarter last year, which suggests a negative year-over-year growth rate of 184.2%. The company is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Viracta Therapeutics will report full year earnings of ($1.44) per share for the current year, with EPS estimates ranging from ($1.64) to ($1.33). For the next year, analysts forecast that the firm will post earnings of ($1.65) per share, with EPS estimates ranging from ($1.85) to ($1.45). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Viracta Therapeutics.

Viracta Therapeutics (NASDAQ:VIRXGet Rating) last released its quarterly earnings data on Wednesday, March 16th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.16.

VIRX has been the topic of several recent research reports. Royal Bank of Canada started coverage on shares of Viracta Therapeutics in a research report on Tuesday, February 1st. They issued an “outperform” rating and a $10.00 price objective on the stock. Zacks Investment Research upgraded shares of Viracta Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 13th.

In other Viracta Therapeutics news, CEO Ivor Royston sold 14,635 shares of the company’s stock in a transaction dated Monday, February 28th. The shares were sold at an average price of $2.78, for a total value of $40,685.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 21,028 shares of company stock worth $58,458. 3.72% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Citigroup Inc. increased its stake in shares of Viracta Therapeutics by 109.6% during the 3rd quarter. Citigroup Inc. now owns 4,206 shares of the company’s stock valued at $34,000 after acquiring an additional 2,199 shares during the last quarter. Advisor Group Holdings Inc. acquired a new position in shares of Viracta Therapeutics during the 3rd quarter valued at about $39,000. Bank of New York Mellon Corp increased its stake in shares of Viracta Therapeutics by 9.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 107,938 shares of the company’s stock valued at $866,000 after acquiring an additional 9,643 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new position in shares of Viracta Therapeutics during the 3rd quarter valued at about $81,000. Finally, Invesco Ltd. acquired a new position in shares of Viracta Therapeutics during the 3rd quarter valued at about $94,000. 56.29% of the stock is owned by institutional investors.

Viracta Therapeutics stock opened at $2.45 on Thursday. Viracta Therapeutics has a 52 week low of $2.18 and a 52 week high of $13.08. The company has a quick ratio of 11.59, a current ratio of 11.59 and a debt-to-equity ratio of 0.05. The firm’s 50-day simple moving average is $3.32 and its 200 day simple moving average is $3.77. The firm has a market capitalization of $91.85 million, a PE ratio of -0.40 and a beta of 2.44.

About Viracta Therapeutics (Get Rating)

Viracta Therapeutics, Inc, a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.

Featured Stories

Get a free copy of the Zacks research report on Viracta Therapeutics (VIRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viracta Therapeutics (NASDAQ:VIRX)

Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.